CD4+ FoxP3+ T regulatory cell subsets in myasthenia gravis patients

Clin Immunol. 2017 Jun:179:40-46. doi: 10.1016/j.clim.2017.03.003. Epub 2017 Mar 9.

Abstract

Although myasthenia gravis (MG) is a classic autoantibody-mediated disease, T cells are centrally involved in its pathogenesis. In recent years a number of studies have analyzed the role of CD4+ FoxP3+ regulatory T cells (Treg) in the disease with contradictory results. Here, the generation of Treg was significantly reduced in thymoma as compared to thymic hyperplasia and normal thymus tissue (p=0.0002). In the peripheral blood, Treg subsets classified according to CD49d, HELIOS and CD45RA expression changed after thymectomy and in the long-term course of immunosuppression. Compared to healthy volunteers the frequency of CD45RA+FoxP3low Treg was reduced in MG patients in general (p=0.037) and in particular in patients without immunosuppression (p=0.036). In our study, thymectomy and immunosuppressive treatment were associated with changes in Treg subpopulations. The reduced frequency of CD45RA+FoxP3low Treg we observed in MG patients might play a role in MG pathogenesis.

Keywords: Autoimmunity; Myasthenia gravis; Regulatory T cells; Thymus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Myasthenia Gravis / drug therapy
  • Myasthenia Gravis / immunology*
  • Myasthenia Gravis / surgery
  • T-Lymphocyte Subsets / drug effects
  • T-Lymphocyte Subsets / immunology*
  • T-Lymphocytes, Regulatory / drug effects
  • T-Lymphocytes, Regulatory / immunology*
  • Thymectomy
  • Thymoma / drug therapy
  • Thymoma / immunology
  • Thymoma / surgery
  • Thymus Gland / pathology
  • Thymus Hyperplasia / drug therapy
  • Thymus Hyperplasia / immunology
  • Thymus Hyperplasia / surgery
  • Thymus Neoplasms / drug therapy
  • Thymus Neoplasms / immunology
  • Thymus Neoplasms / surgery

Substances

  • Immunosuppressive Agents